News und Analysen
DGAP-News: MicroVision to Participate in Upcoming Investor Conferences
Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Sensorion Announces the Publication of Its 2021 Annual Financial Report
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
DGAP-News: Abivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
Simulations Plus Successfully Delivers FDA-Funded Project
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the completion of a newly funded
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data from the ATHENA-MONO Phase 3 clinical trial evaluating Rubraca
Pfizer Declares Second-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 second-quarter 2022 dividend on the company’s common stock, payable June 10, 2022, to holders of the Common
IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today
Novocure Reports First Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
MD Medical Group Investments Plc: Results of the Annual General Meeting of Shareholders
Sensorion Full-Year 2021 Financial Results and Business Highlights
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005801/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
MD Medical Group Investments Plc: MDMG reports 8% growth in Revenue in Q1 2022
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
DGAP-News: MicroVision Announces First Quarter 2022 Results
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology
ICON Reports First Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the first quarter ended March 31, 2022.
CEO Dr. Steve
DexCom präsentiert auf der internationalen ATTD-Konferenz sein erweitertes CGM-Portfolio, das Menschen mit Diabetes mehr Wahlmöglichkeiten bietet
DexCom, Inc. (Nasdaq: DXCM), der Weltmarktführer im Bereich des kontinuierlichen Glukosemonitoring für Diabetespatienten, wird auf der 15. International Conference on Advanced Technologies and
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant)
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with